- Home
- CYH vs SABS Comparison
CYH vs SABS Comparison
Compare CYH & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CYH | SABS |
|---|---|---|
| Founded | 1985 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hospital/Nursing Management | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 410.3M | 336.6M |
| IPO Year | 2000 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CYH | SABS |
|---|---|---|
| Price | $2.98 | $3.70 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 4 |
| Target Price | $3.28 | ★ $10.75 |
| AVG Volume (30 Days) | ★ 1.7M | 434.3K |
| Earning Date | 04-21-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 196.67 | 78.53 |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $12,485,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.17 | N/A |
| P/E Ratio | $32.44 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.41 | $1.85 |
| 52 Week High | $4.43 | $5.15 |
Technical Indicators
Market Signals| Indicator | CYH | SABS |
|---|---|---|
| Relative Strength Index (RSI) | 47.37 | 49.38 |
| Support Level | $2.89 | $3.68 |
| Resistance Level | $2.99 | $4.03 |
| Average True Range (ATR) | 0.11 | 0.16 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 57.18 | 45.16 |
Price Performance
Historical ComparisonAbout CYH Community Health Systems Inc.
Community Health Systems Inc is a publicly owned hospital operator in the United States. The company also owns four home health agencies and provides management and consulting services to independent hospitals. The firm derives revenue through a broad range of general and specialized hospital healthcare services and outpatient services.
About SABS SAB Biotherapeutics Inc.
SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.